Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

3.7K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.7K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

5.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.2K
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

8.2K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
8.2K
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.0K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.0K
Crossover Experiments01:16

Crossover Experiments

3.1K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
3.1K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.4K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of quinazoline-based derivatives as novel autophagy inhibitors in pancreatic cancer.

Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents·2026
Same author

Electronic Modulation via Introducing Polyoxometalate to Fe-Ni<sub>3</sub>S<sub>2</sub> Nanosheet for Enhanced Water Electrolysis.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Analysis of complete blood counts and derived inflammatory indices with non-suicidal self-injury and suicide attempt in adolescents with major depressive disorder.

Frontiers in psychiatry·2026
Same author

Therapeutic Efficacy of Xuanfei Zhisou Decoction Combined with Baduanjin in Treating Wind-Dryness-Induced Cough Following Viral Respiratory Infections.

The Tohoku journal of experimental medicine·2026
Same author

Handling missing data in longitudinal randomized clinical trials within the framework of targeted learning under MAR and MNAR.

Contemporary clinical trials·2026
Same author

Surface phosphating activation of PtMo<sub>6</sub>-Ni-BDC nanosheets for an enhanced hydrogen evolution reaction.

Nanoscale·2026

Related Experiment Video

Updated: Sep 16, 2025

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.9K

2-in-1 adaptive design with dose optimization accounting for ranked dose response.

Man Jin1, Pingye Zhang2

  • 1AbbVie Inc, North Chicago, IL, USA.

Contemporary Clinical Trials
|July 5, 2025
PubMed
Summary

This study introduces a novel 2-in-1 adaptive design for oncology clinical trials, streamlining drug development by integrating Phase 2 and Phase 3 seamlessly. This approach enhances efficiency, especially for treatments with delayed effects.

Keywords:
2-in-1 adaptive designDose optimizationRanked dose responseSeamless phase 2/3 trial

More Related Videos

Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.3K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K

Related Experiment Videos

Last Updated: Sep 16, 2025

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.9K
Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.3K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K

Area of Science:

  • Clinical Trials Methodology
  • Oncology Drug Development
  • Biostatistics

Background:

  • Adaptive clinical trial designs offer flexibility in oncology drug development.
  • Seamless 2-in-1 designs aim to expedite the transition from early to late-stage trials.
  • Current methods may not fully optimize for delayed treatment effects.

Purpose of the Study:

  • To propose and evaluate a novel seamless 2-in-1 adaptive design for oncology clinical trials.
  • To integrate Phase 2 dose-finding with Phase 3 confirmatory trials.
  • To assess the statistical performance of the proposed design, considering dose rank and delayed treatment effects.

Main Methods:

  • Development of a 2-in-1 adaptive design allowing Phase 2 expansion into Phase 3.
  • Incorporation of selected dose rank into statistical testing procedures.
  • Monte Carlo simulations to evaluate Type I error rate and statistical power.

Main Results:

  • The proposed 2-in-1 adaptive design demonstrated favorable operating characteristics in simulations.
  • The design is particularly advantageous when the treatment effect is delayed.
  • Statistical validity (Type I error) and power were assessed under various scenarios.

Conclusions:

  • The seamless 2-in-1 adaptive design offers an efficient pathway for oncology drug development.
  • This innovative design is beneficial for drugs with delayed efficacy.
  • The methodology accounts for dose selection and statistical rigor in adaptive trials.